Limitations in resectability of colorectal liver metastases 2020 - A systematic approach for clinicians and patients.

Colorectal liver metastases Conversion chemotherapy Parenchymal sparing hepatectomy Peri-operative mortality Regenerative liver surgery Resectability Two-stage hepatectomy

Journal

Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218

Informations de publication

Date de publication:
06 2021
Historique:
received: 21 08 2020
accepted: 12 09 2020
pubmed: 28 9 2020
medline: 4 3 2022
entrez: 27 9 2020
Statut: ppublish

Résumé

Colorectal liver metastases (CRLM) affect over 50 % of all patients with colorectal cancer, which is the second leading cause of cancer in the western world. Resection of CRLM may provide cure and improves survival over chemotherapy alone. However, resectability of CLRM has to be decided in multidisciplinary tumor boards and is based on oncological factors, technical factors and patient factors. The advances of chemotherapy lead to the abolition of contraindications to resection in favor of technical resectability, but somatic mutations and molecular subtyping may improve selection of patients for resection in the future. Technical factors center around anatomy of the lesions, volume of the remnant liver and quality of the liver parenchymal. Multiple strategies have been developed to overcome volume limitations and they are reviewed here. The least investigated topic is how to select the right patients among an elderly and frail patient population for the large variety of technical options specifically for bi-lobar CRLM to keep 90-day mortality as low as possible. The review is an overview over the current state-of-the art and a systematic guide to the topic of resectability of CRLM for both clinicians and patients.

Identifiants

pubmed: 32980499
pii: S1044-579X(20)30199-1
doi: 10.1016/j.semcancer.2020.09.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

10-20

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Erik Schadde (E)

Division of Surgical Oncology and Division of Transplant Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL, USA; Institute of Physiology, University of Zurich, Zurich, Switzerland; Department of Surgery, Cantonal Hospital Winterthur, Zurich, Switzerland. Electronic address: erik.schadde@icloud.com.

Dirk J Grunhagen (DJ)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Cornelis Verhoef (C)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Lucyna Krzywon (L)

McGill University, Montreal, Canada.

Peter Metrakos (P)

McGill University, Montreal, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH